News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website

 

Dr. Kurt Jaeckle to Lead Phase III Clinical Trial of Novel Drug VAL-083 for Late-Stage Glioblastoma

Al's Comment:

 This is a trial for recurrent glioblastoma patients who have failed Temodar and Avastin.  There is another trial of Val-083 for newly diagnosed MGMT unmethylated patients.  Val-083 is a chemotherapy similar  to Temodar but works at a different location on the DNA of the tumor cells.  It should theoretically not be affected by the MGMT status and may work even when the tumor is resistant to Temodar


Posted on: 01/10/2018

Dr. Kurt Jaeckle to Lead Phase III Clinical Trial of Novel Drug VAL-083 for Late-Stage Glioblastoma

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740